{"disease":{"id":"amyloidosis-hereditary","name":"amyloidosis hereditary"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT01164241","title":"Natural History of Severe Allergic Inflammation and Reactions","phase":"","overall_status":"COMPLETED","enrollment_count":945,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05489549","title":"Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT06573723","title":"Institutional Registry of Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":380,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT03759379","title":"HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT07314268","title":"ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT07080268","title":"Validation of a Questionnaire for Quality of Life Assessment in Patients With Transthyretin Amyloidosis.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"Hospital General de Niños Pedro de Elizalde","has_results":false},{"nct_id":"NCT07033715","title":"Exercise in Hereditary ATTR (ATTRv) Amyloidosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"University of Maia","has_results":false},{"nct_id":"NCT02939820","title":"Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT03400098","title":"ATTR Expanded Access Program (EAP) by Ionis","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}